Skip to content

effect of omega 3 in tobacco chewers with difficulty in mouth opening

Clinical assessment of efficacy of Omega 3 in Oral Submucous Fibrosis patients treated with intralesional steroid and hyaluronidase therapy ââ?¬â??A randomized controlled trial.

Status
Active, not recruiting
Phases
Unknown
Study type
Interventional
Source
CTRI
Registry ID
CTRI/2017/09/009953
Enrollment
40
Registered
2017-09-28
Start date
Unknown
Completion date
Unknown
Last updated
2022-10-17

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Health Condition 1: K135- Oral submucous fibrosis Health Condition 2: null- oral submucous fibrosis type II and III

Interventions

Intervention1: omega 3 hyaluronidase and dexamethasone injection: omega 3 1gm three times daily for three months dexamethasone 1.5ml and hyaluronidase 1500 IU to be injected biweekly in buccal mucos

Sponsors

Dr Milanjeet Kaur
Lead Sponsor

Eligibility

Inclusion criteria

Inclusion criteria: 1.patients who are more than 18 years in age 2. Patients suffering from chronic oral submucous fibrosis lesions characterised by burning sensations in the mouth, particularly while taking hot and spicy food. 3.Patients who are physically healthy & well oriented in time, space & as a person. 4. Patients not on any treatment for the same. In case they are, then such treatment will be stopped & a wash out period of 2 weeks will be given 5.Patients who will agree to whole examination, undergo treatment & will be willing for evaluation every month for 6 month & one year

Exclusion criteria

Exclusion criteria: 1.Patients suffering from any other systemic diseases like diabetes, Hypertension, Cardiovascular system disease, renal function, liver disorders etc. 2.Patients with any other mucosal disease or any other skin lesions which may be associated with oral lesions 3.Patients on any drug therapy. 4.Patients with findings of any physical or mental abnormality which would interfere with or be affected by the study procedure. 5.Patients with a known allergy or contraindication to study medications

Design outcomes

Primary

MeasureTime frame
interincisal distance tongue protrusion cheek flexibility burning sensation visual analogue scaleTimepoint: initial at 0 month i.e. pre operative, 1 month, 2 months, 3 months, 6 months and 1 year.

Secondary

MeasureTime frame
any other sign and symptomTimepoint: first second third sixth month and one year after treatment

Countries

India

Contacts

Public ContactDr Milanjeet kaur

Dr D Y Patil dental college and hospital

drdmsable@gmail.com9766343410

Outcome results

None listed

Source: CTRI (via WHO ICTRP) · Data processed: Feb 4, 2026